Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
05 mars 2023 14h00 HE
|
Lumos Pharma, Inc.
Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics of OraGrowtH210 Trial Subjects Highlighted in...
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
01 mars 2023 16h05 HE
|
Lumos Pharma, Inc.
-- Patient Enrollment Completed in OraGrowtH210 and OraGrowtH212 Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected Q4 2023 -- -- Additional Data from OraGrowtH Trials to...
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
28 févr. 2023 16h05 HE
|
Lumos Pharma, Inc.
Phase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled Primary Outcome Data for Both OraGrowtH Trials Expected 4Q 2023 AUSTIN, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lumos...
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
15 févr. 2023 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
03 janv. 2023 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
12 déc. 2022 07h30 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the...
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
29 nov. 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will...
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
22 nov. 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials...
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
14 nov. 2022 06h10 HE
|
Lumos Pharma, Inc.
-- Interim Data for Potentially the First Oral Medication for PGHD from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials Met Expectations with an Encouraging Growth Response of 8.6 cm/yr at six...
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
14 nov. 2022 06h00 HE
|
Lumos Pharma, Inc.
- LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) - - Interim...